Cassava Sciences, Inc. Profile Avatar - Palmy Investing

Cassava Sciences, Inc.

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational dia…

Biotechnology
US, Austin [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Cassava Sciences, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of SAVA's Analysis
CIK: 1069530 CUSIP: 14817C107 ISIN: US14817C1071 LEI: - UEI: -
Secondary Listings
SAVA has no secondary listings inside our databases.